drugset / Trial / NCT01786239

Omega-3 Dietary Supplements in Schizophrenia

NCT01786239

RandomizedSingle-groupQuadruple-blindTreatment

Summary

This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.

Timeline

Start
2013-05
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Omega-3 fatty acids Unknown 400 mg
Subject Omega-3 fatty acids Unknown 740 mg
Background Risperidone Other / unclassified 1 mg
Background Risperidone Other / unclassified 6 mg